Health
15 Oct 2026
Verastem’s KRAS‑G12D Drug Shows Early Promise in Small Trial
Early data from a Phase 1/2 study of Verastem’s VS‑7375 suggest it may reduce tumor growth in patients with pancreatic, colorectal and lung cancers carrying the G12D mutation.
Read more